PORTFOLIA

Portfolia FemTech Fund, LLC

(A Delaware Limited Liability Company)

Financial Statements
As of and for the year ended December 31, 2023 (Unaudited)

Vintage Year: 2018

Fund Data as of: 12/31/2023

INVESTOR METRICS		<u>Member</u>		<u>Member</u>	
Commitment Paid-in	,	\$	3,233,500 3,233,500	\$	3,358,500 3,358,500
Net Asset Value Distributions			3,423,815		3,626,714
Total value	[5	\$	3,423,815	\$	3,626,714
TVPI			1.06x		1.08x
DPI			0.00x		0.00x
RVPI			1.06x		1.08x
Net IRR			1.09%		

PORTFOLIO METRICS		٦
Cash invested	\$ 2,992,869)
# of current investments	8	3
# of realized investments	1	Ĺ
Total # of investments	g)
Realized	_	
Investments at Fair Value	3,600,999)
Total value	\$ 3,600,999)
Gross TVPI	1.20)x
Gross IRR	4.869	%

^{**} Gross IRR based on portfolio investments data and not contributed capital of members

Key definitions

PI: Paid-in Capital - total capital contributions to the fund

RV: Residual Value - remaining value in the fund

D: Distributions - value of cash and stock returned to members

TV: Total Value - RV + D

TVPI: Ratio of TV:PI DPI: Ratio of D:PI RVPI: Ratio of RV:PI

IRR: Internal Rate of Return - annual rate of growth an investment is expected to generate.

Gross: returns from portfolio companies to the fund before deducting management fee, carried interest, and other fund expenses. Net: returns to members net of management fees, carried interest, and other fund expenses.

Portfolia FemTech Fund, LLC (A Delaware Limited Liability Company) Schedule of Portfolio Investments December 31, 2023 (Unaudited)

	Initial Purchase Date	# Units		Cost		Fair Value		nrealized preciation preciation)
Aeena Dx Inc. (fka Prime Genomics) Series A Preferred	06/25/19	500,000	\$	500,000	\$	86,207	\$	(442.702)
Convertible Note 8% Convertible Note 8%	12/03/21 06/01/22	N/A N/A	Φ	14,650 36,221	Ф	14,650 36,221	Ф	(413,793) - -
Aria CV Inc. Series B Preferred	02/01/20	138,875		500,000		500,000		-
Bone Health Technologies Inc. Series A Preferred	01/01/20	367,647		250,000		352,941		102,941
Future Family Inc. Common Stock	09/06/18	84,231		200,000		98,592		(101,408)
Madorra Inc. Series A1 Preferred SAFE	05/17/19 12/01/20	503,144 N/A		399,999 28,000		399,999 28,000		- -
Maven Clinic Inc. Series C Preferred	05/01/20	100,022		499,998		1,770,389		1,270,391
Sana Health Inc. Series Seed Preferred	01/01/20	46,481		100,000		100,000		-
Willow Innovations, Inc. Convertible Note 8%	06/24/22	N/A		214,000		214,000		-
Total Investments			\$	2,742,868	\$	3,600,999	\$	858,131

(A Delaware Limited Liability Company)

Schedule of Realized Portfolio Investments Inception to date ended December 31, 2023 (Unaudited)

Company	Purchase Date	Disposition Date	# Units	 Cost		Proceeds/ Shares Received		Proceeds Receivable		Net Realized Gain / (Loss)	
Solace Theraputics	04/01/2020	06/20/2022	625,000	\$ 250,000	\$	-	\$	-	\$	(250,000)	
		Total		\$ 250.000	\$	-	\$	-	\$	(250.000)	

(A Delaware Limited Liability Company)

Statement of Net Assets

December 31, 2023

(Unaudited)

Assets Investments at fair value (cost \$2,742,868) Cash Interest receivable Total assets	\$ 3,600,999 501 33,112 3,634,612
Liabilities Due to related party Total liabilities	7,898 7,898
Net assets	\$ 3,626,714
Net assets represented by members' capital Capital contributions Net investment expense Net realized loss on investments Net unrealized appreciation on investments	\$ 3,358,500 (339,917) (250,000) 858,131
Total members' capital	\$ 3,626,714

(A Delaware Limited Liability Company)

Statement of Operations

For the year ended December 31, 2023

(Unaudited)

Income	
Interest income	\$ 21,190
Total income	21,190
Expenses	
Management fee	33,535
Legal and professional fees	665
Other expenses	 9,143
Total expenses	 43,343
Net investment expense	\$ (22,153)
Unrealized appreciation on investments	
Balance, beginning of the period	1,164,263
Balance, end of the period	 858,131
Net change in unrealized appreciation on investments	 (306,132)
Net decrease in net assets from operations	\$ (328,285)

(A Delaware Limited Liability Company)

Statement of Changes in Members' Capital For the year ended December 31, 2023

(Unaudited)

Balances, January 1, 2023	\$ 3,954,999
Net investment expense Net change in unrealized appreciation	(22,153) (306,132)
Balances, December 31, 2023	\$ 3,626,714